source
- Pfizer signs $2.6 billion China deal to develop in-vivo CAR-T therapies for autoimmune diseasePfizer announced a collaboration with Chinese biotech Starna Therapeutics to pursue in-vivo CAR-T cell therapies aimed at autoimmune disorders. Under the agreement, Pfizer will receive exclusive r…
- FDA issues complete response letter rejecting Summit Therapeutics' lung cancer drugThe U.S. Food and Drug Administration released a complete response letter that rejects Summit Therapeutics' lung cancer candidate, providing the agency’s detailed reasons for the decision. The age…